Snowden Capital Advisors LLC Sells 209 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Snowden Capital Advisors LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,309 shares of the medical research company’s stock after selling 209 shares during the quarter. Snowden Capital Advisors LLC’s holdings in IQVIA were worth $454,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Siemens Fonds Invest GmbH lifted its position in IQVIA by 973.2% during the 4th quarter. Siemens Fonds Invest GmbH now owns 21,345 shares of the medical research company’s stock valued at $4,195,000 after purchasing an additional 19,356 shares during the period. Shell Asset Management Co. lifted its position in IQVIA by 15.2% during the 4th quarter. Shell Asset Management Co. now owns 5,293 shares of the medical research company’s stock valued at $1,040,000 after purchasing an additional 699 shares during the period. Royal Bank of Canada lifted its position in IQVIA by 4.2% during the 4th quarter. Royal Bank of Canada now owns 472,186 shares of the medical research company’s stock valued at $92,789,000 after purchasing an additional 18,911 shares during the period. Rafferty Asset Management LLC lifted its position in IQVIA by 10.3% during the 4th quarter. Rafferty Asset Management LLC now owns 20,466 shares of the medical research company’s stock valued at $4,022,000 after purchasing an additional 1,916 shares during the period. Finally, Raiffeisen Bank International AG acquired a new position in IQVIA during the 4th quarter valued at about $1,572,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of analyst reports. HSBC downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. UBS Group cut their price target on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Robert W. Baird cut their price target on shares of IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Finally, Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $228.14.

IQVIA Price Performance

Shares of IQV opened at $137.34 on Thursday. The stock has a market capitalization of $23.76 billion, a P/E ratio of 18.31, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a 50 day moving average of $157.30 and a 200-day moving average of $184.65. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts’ expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the business earned $2.54 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.